CN1114690C - 乳头瘤假病毒及其制备方法 - Google Patents
乳头瘤假病毒及其制备方法 Download PDFInfo
- Publication number
- CN1114690C CN1114690C CN01118003A CN01118003A CN1114690C CN 1114690 C CN1114690 C CN 1114690C CN 01118003 A CN01118003 A CN 01118003A CN 01118003 A CN01118003 A CN 01118003A CN 1114690 C CN1114690 C CN 1114690C
- Authority
- CN
- China
- Prior art keywords
- pseudovirus
- papilloma
- plasmid
- virus
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001112090 Pseudovirus Species 0.000 title claims abstract description 43
- 208000003154 papilloma Diseases 0.000 title claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000013612 plasmid Substances 0.000 claims abstract description 21
- 229960005486 vaccine Drugs 0.000 claims abstract description 11
- 239000002245 particle Substances 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 24
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 238000013016 damping Methods 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- PSYGHMBJXWRQFD-UHFFFAOYSA-N 2-(2-sulfanylacetyl)oxyethyl 2-sulfanylacetate Chemical compound SCC(=O)OCCOC(=O)CS PSYGHMBJXWRQFD-UHFFFAOYSA-N 0.000 claims description 4
- VMVZMFMKKYTBEF-UHFFFAOYSA-N 2-aminoethanol tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.NCCO VMVZMFMKKYTBEF-UHFFFAOYSA-N 0.000 claims description 4
- 241000701822 Bovine papillomavirus Species 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 4
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 210000002445 nipple Anatomy 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 5
- 238000001415 gene therapy Methods 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 210000004877 mucosa Anatomy 0.000 abstract description 2
- 230000008105 immune reaction Effects 0.000 abstract 3
- 210000002751 lymph Anatomy 0.000 abstract 2
- 108010041986 DNA Vaccines Proteins 0.000 abstract 1
- 229940021995 DNA vaccine Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000009897 systematic effect Effects 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 210000004400 mucous membrane Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 5
- 238000011238 DNA vaccination Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20061—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01118003A CN1114690C (zh) | 2001-05-15 | 2001-05-15 | 乳头瘤假病毒及其制备方法 |
| JP2001321828A JP4511090B2 (ja) | 2001-05-15 | 2001-10-19 | Ｄｎａプラスミドワクチン用アジュバンド及びその調製方法 |
| PCT/CN2002/000187 WO2002092796A1 (en) | 2001-05-15 | 2002-03-22 | Papilloma pseud-virus and it's preparation |
| US10/294,087 US6878541B2 (en) | 2001-05-15 | 2002-11-14 | Papilloma pseudo-virus and preparation |
| US11/060,034 US7205126B2 (en) | 2001-05-15 | 2005-02-17 | Papilloma pseudovirus and preparation |
| US11/784,626 US8129144B2 (en) | 2001-05-15 | 2007-04-09 | Papilloma pseudovirus and preparation |
| JP2007124042A JP4472724B2 (ja) | 2001-05-15 | 2007-05-09 | パピロマウイルス偽ウイルス及びその調製方法 |
| US13/413,386 US20120164173A1 (en) | 2001-05-15 | 2012-03-06 | Papilloma Pseudovirus and Preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01118003A CN1114690C (zh) | 2001-05-15 | 2001-05-15 | 乳头瘤假病毒及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1333338A CN1333338A (zh) | 2002-01-30 |
| CN1114690C true CN1114690C (zh) | 2003-07-16 |
Family
ID=4662911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01118003A Expired - Fee Related CN1114690C (zh) | 2001-05-15 | 2001-05-15 | 乳头瘤假病毒及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US6878541B2 (enExample) |
| JP (2) | JP4511090B2 (enExample) |
| CN (1) | CN1114690C (enExample) |
| WO (1) | WO2002092796A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120164173A1 (en) * | 2001-05-15 | 2012-06-28 | Liang Qiao | Papilloma Pseudovirus and Preparation |
| CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
| WO2006113209A1 (en) | 2005-04-15 | 2006-10-26 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
| US8394411B2 (en) | 2007-05-08 | 2013-03-12 | The United States of America as represented by the Secretary, Dept. of Health and Human Services National Institutes of Health | Papillomavirus pseudoviruses for detection and therapy of tumors |
| US9724404B2 (en) | 2009-04-13 | 2017-08-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | HPV particles and uses thereof |
| WO2011039646A2 (en) | 2009-09-30 | 2011-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Papilloma virus -like particles for targeted gene delivery |
| WO2011053675A2 (en) | 2009-10-30 | 2011-05-05 | Cns Therapeutics, Inc. | Improved neurturin molecules |
| WO2013119877A1 (en) | 2012-02-07 | 2013-08-15 | Aura Biosciences, Inc. | Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells |
| AU2013221317B2 (en) | 2012-02-16 | 2017-07-06 | Pangu Biopharma Limited | Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases |
| EP4059521A1 (en) | 2013-09-18 | 2022-09-21 | Aura Biosciences, Inc. | Virus-like particle conjugates for diagnosis and treatment of tumors |
| AU2016343722A1 (en) | 2015-10-30 | 2018-05-24 | Aleta Biotherapeutics, Inc. | Targeted cancer therapy |
| MX2018005315A (es) | 2015-10-30 | 2018-08-14 | Aleta Biotherapeutics Inc | Composiciones y metodos para el tratamiento del cancer. |
| WO2017075533A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| US10751398B2 (en) * | 2016-10-07 | 2020-08-25 | Loyola University Chicago | Inflammasome activators and methods of use to treat tumors |
| JP2020524710A (ja) * | 2017-06-23 | 2020-08-20 | パソヴァックス エルエルシー | 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用 |
| CN120392995A (zh) | 2017-11-06 | 2025-08-01 | 美利坚合众国,由健康及人类服务部部长代表 | 利用预先存在的微生物免疫的癌症治疗 |
| WO2019096796A1 (en) | 2017-11-14 | 2019-05-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Non-human papillomaviruses for gene delivery in vitro and in vivo |
| SG11202106931PA (en) | 2018-12-27 | 2021-07-29 | Verimmune Llc | Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19526752C2 (de) * | 1995-07-21 | 1997-08-07 | Lutz Prof Dr Gissmann | Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln |
| FR2749323B1 (fr) * | 1996-06-04 | 1998-07-10 | Pasteur Merieux Serums Vacc | Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique |
| DE69734829D1 (de) * | 1996-07-17 | 2006-01-12 | Us Health | Infektiöse pseudovirale papillomavirus partikel |
| EP1700911B1 (en) * | 1997-09-05 | 2016-04-06 | Medimmune, Inc. | In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs) |
| GB9806666D0 (en) * | 1998-03-27 | 1998-05-27 | Stanley Margaret | Antigen preparation and use |
| CN1241636A (zh) * | 1999-07-05 | 2000-01-19 | 第一军医大学珠江医院 | 抗hpv16e6核酶质粒及其在人乳头瘤病毒与肿瘤治疗中的应用 |
| GB0007231D0 (en) * | 2000-03-24 | 2000-05-17 | Chiron Spa | Modified rna for gene delivery |
| CN1114690C (zh) | 2001-05-15 | 2003-07-16 | 乔良 | 乳头瘤假病毒及其制备方法 |
-
2001
- 2001-05-15 CN CN01118003A patent/CN1114690C/zh not_active Expired - Fee Related
- 2001-10-19 JP JP2001321828A patent/JP4511090B2/ja not_active Expired - Fee Related
-
2002
- 2002-03-22 WO PCT/CN2002/000187 patent/WO2002092796A1/zh not_active Ceased
- 2002-11-14 US US10/294,087 patent/US6878541B2/en not_active Expired - Lifetime
-
2005
- 2005-02-17 US US11/060,034 patent/US7205126B2/en not_active Expired - Fee Related
-
2007
- 2007-04-09 US US11/784,626 patent/US8129144B2/en not_active Expired - Fee Related
- 2007-05-09 JP JP2007124042A patent/JP4472724B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6878541B2 (en) | 2005-04-12 |
| US7205126B2 (en) | 2007-04-17 |
| JP4511090B2 (ja) | 2010-07-28 |
| US20030129728A1 (en) | 2003-07-10 |
| JP4472724B2 (ja) | 2010-06-02 |
| JP2003024058A (ja) | 2003-01-28 |
| US20100255027A1 (en) | 2010-10-07 |
| CN1333338A (zh) | 2002-01-30 |
| JP2007211026A (ja) | 2007-08-23 |
| WO2002092796A1 (en) | 2002-11-21 |
| US8129144B2 (en) | 2012-03-06 |
| US20050142115A1 (en) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1114690C (zh) | 乳头瘤假病毒及其制备方法 | |
| JP5153984B2 (ja) | 口蹄疫に対するワクチン | |
| CN108567974B (zh) | 一种防治新型鹅星状病毒的灭活疫苗及其制备方法 | |
| EP2802349B1 (en) | Immunogenic hpv l2-containing vlps and related compositions and methods | |
| US6368602B1 (en) | Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine | |
| CN105497886A (zh) | 乙肝核心抗原病毒样颗粒作为肿瘤治疗性疫苗载体的应用 | |
| JP2003523401A (ja) | 粘膜体表面に接触させてワクチン抗原を包含する物質の効果を調節する新規非抗原性粘膜アジュバント処方 | |
| JP7777890B2 (ja) | Ｃｃｌ１１の用途 | |
| BR112019027488A2 (pt) | partículas semelhantes a vírus quiméricas e usos destas como redirecionadores de respostas imunológicas antígeno-específicos | |
| CN116200394A (zh) | CpG寡聚脱氧核苷酸及其应用 | |
| EP2032165A1 (en) | Bioactive purified hspe7 compositions | |
| CN103796673A (zh) | Dna疫苗 | |
| JP2020510052A (ja) | 免疫賦活薬、免疫療法用医薬組成物、ならびにその調製および使用 | |
| CN119113096A (zh) | 防治SARS-CoV-2变异株JN.1、BA.2.86和XBB谱系的重组蛋白疫苗、联合用药物及用途 | |
| Somavarapu et al. | Oral plasmid DNA delivery systems for genetic immunisation | |
| CN102626514A (zh) | 一种甲鱼系统性败血症球状病毒灭活疫苗及其制备方法 | |
| CN102266551B (zh) | 可用于治疗人或动物免疫相关性疾病的白介素-4治疗性疫苗 | |
| CN114470186B (zh) | 一种可吸入式纳米新冠疫苗的制备方法 | |
| CN117860879A (zh) | 一种纳米疫苗递送系统及其制备方法和应用 | |
| KR101209141B1 (ko) | 독성약화된 토끼 믹소마바이러스를 기본으로 한모노파라뮤니티 유발인자 | |
| US20120164173A1 (en) | Papilloma Pseudovirus and Preparation | |
| CN107456574B (zh) | 一种无佐剂单剂量HBsAg纳米凝胶疫苗及其制备方法 | |
| KR102092258B1 (ko) | 광감각제가 접합된 고분자를 유효성분으로 포함하는 면역증강제, 바이러스 감염 또는 암 예방 또는 치료용 백신 조성물 | |
| CN1322120C (zh) | 乙肝乙脑双价疫苗 | |
| WO2025246436A1 (en) | Circular rna-based therapeutic vaccine for treating hpv positive cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1057795 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20030716 Termination date: 20140515 |